重组人uPAR/PLAUR蛋白 Human uPAR/PLAUR Protein(His-Avi标签)(93848ES)
产品应用
The urokinase-type Plasminogen Activator (uPA) is one of two activators that converts the extracellular zymogen plasminogen to plasmin, a serine protease that is involved in a variety of normal and pathological processes that require cell migration and/or tissue destruction.Both the scuPA and tcuPA bind with high-affinity to the cell surface via the glycosyl phosphatidylinositol-linked receptor uPAR which serves to localize the uPA proteolytic activity.
高纯度、高活性、低内毒素、高批间一致性
Bis-Tris PAGE

Human uPAR on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
SEC-HPLC

The purity of Human uPAR is greater than 95% as determined by SEC-HPLC.
ELISA Data

Immobilized Human uPAR, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human PLAU, His-Avi Tag with the EC50 of 15.3ng/ml determined by ELISA.
-25 ~ -15℃保存,收到货之后有效期1年。
复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。
【应用方向】HER2与HER3:ErbB受体家族协同靶向治疗的核心工具蛋白
249
2026-08-31
【应用方向】HER2:抗体药物研发的核心工具蛋白
259
2026-08-31
【应用方向】抗体药研发中常见靶点蛋白及其应用
328
2026-08-31
【应用方向】靶点蛋白在抗体药研发中的应用
247
2026-08-31
【应用方向】GPC3:HCC靶向治疗的核心靶点与药物研发探索
2220
2026-04-24
【应用方向】TROP2:从分子机制到实体瘤靶向治疗的研究进展
2076
2026-04-24
【应用方向】4-1BB-4-1BBL共刺激轴的T细胞活化机制
1280
2026-04-22
【应用方向】TNFR蛋白家族概述
1256
2026-04-21
【应用方向】Klotho蛋白:编织生命之线的抗衰老分子
1456
2026-04-20
【应用方向】药靶明星 | FGFRs家族蛋白解析
1060
2026-04-20
【应用方向】解析Fc受体:抗体药物研发的核心靶点与评价基石
1081
2026-04-20
【应用方向】FcγR家族:抗体药物研发的基石与核心靶点
1200
2026-04-20
【应用方向】CD47-SIRPα轴研究工具与药物开发应用
964
2026-04-20
【应用方向】HER2靶点蛋白:驱动肿瘤靶向治疗的核心力量
14782
2026-03-02
【技术讲解】细胞因子科学选型--常见问题解答
11386
2026-09-21





